Vaxart, Inc.
NASDAQ:VXRTBiotechnology
Healthcare
$0.53 -1.75%
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
52W Low $0.26High $0.84
Volume 0.12M
Average 0.41M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$7.71M
FY 2025 · Annual
Investing Cash Flow
$16.63M
FY 2025 · Annual
Financing Cash Flow
$4.24M
FY 2025 · Annual
-92.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.47M) | (107.76M) | (82.47M) | (66.95M) | 16.33M |
| Depreciation & Amortization | 4.21M | 5.81M | 8.62M | 8.85M | 8.58M |
| Deferred Income Tax | 3.09M | 4.09M | 0 | 0 | 0 |
| Stock-Based Compensation | 8.87M | 13.59M | 14.13M | 11.5M | 8.31M |
| Change in Working Capital | (2.12M) | (4.7M) | (10.85M) | 3.26M | (22.56M) |
| Accounts Receivables | 263K | 51K | (2.99M) | (2.75M) | (39.38M) |
| Inventory | 0 | (7.11M) | 0 | 0 | 0 |
| Accounts Payables | 1.63M | 357K | (2.44M) | 5.27M | 14.64M |
| Other Working Capital | (4.01M) | 2M | (5.42M) | 742K | 2.17M |
| Other Non-Cash Items | (3.41M) | (5.81M) | 106K | (1.43M) | (2.94M) |
| Operating Cash Flow | (59.83M) | (94.78M) | (70.45M) | (44.76M) | 7.71M |
| Capital Expenditures | (5.16M) | (9.6M) | (1.87M) | (554K) | (145K) |
| Acquisitions (Net) | (4.83M) | 10.81M | 120K | 0 | 0 |
| Purchases of Investments | (44.81M) | (55.01M) | (27.5M) | (54.33M) | (19.03M) |
| Sales of Investments | 5.7M | 44.2M | 73.2M | 43.5M | 40M |
| Other Investing Activities | 0 | (10.81M) | 0 | (9.95M) | (4.2M) |
| Investing Cash Flow | (49.1M) | (20.42M) | 43.95M | (21.32M) | 16.63M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 122.21M | 17.24M | 15.03M | 56.78M | 4.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | 225K | 213K | (214K) | (199K) |
| Financing Cash Flow | 125.8M | 17.46M | 15.24M | 56.56M | 4.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.88M | (97.73M) | (11.26M) | (9.53M) | 28.59M |
| Free Cash Flow | (64.99M) | (104.38M) | (72.32M) | (45.32M) | 7.57M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$16.3M
+ D&A$8.6M
+ Stock-Based Comp$8.3M
+ Deferred Tax$0
- Working Capital-$22.6M
- Other Non-Cash-$2.9M
= Operating Cash Flow$7.7M
- Capex-$145.0K
= Free Cash Flow$7.6M
Analysis
FY2025 free cash flow is $7.6M. FCF conversion is 46.4% of net income. Operating cash flow was $7.7M, with capex of -$145.0K. The largest bridge item is Working Capital at -$22.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEFA14A | DEFA14A filing | Jul 2, 2026 | |
| 8-K | Current report | Jul 2, 2026 | |
| DFAN14A | DFAN14A filing | Jul 2, 2026 | |
| DEFA14A | DEFA14A filing | Jul 1, 2026 | |
| 8-K | Current report | Jun 26, 2026 |
Does VXRT generate free cash flow?
Vaxart, Inc. (VXRT) generated $7.57M of free cash flow in fiscal 2025.
How much operating cash flow does VXRT produce?
Operating cash flow was $7.71M, before capital expenditures of $145,000.00.
Continue the stock analysis
Jump to another research area for this company.